HER2-Low Breast Cancer Mirrors HER2-0 in Metastasis Timing but Confers a Survival Edge

The boundary between breast cancer categories has never been as sharp as laboratory reports might suggest, and few borders have proven as blurry as the one separating tumors with no HER2 expression from those with just a whisper of it. A new retrospective study published in Breast Cancer Research and Treatment now offers one of the most detailed looks yet at how these categories behave once breast cancer has spread beyond the breast. Analyzing 1,599 patients with metastatic breast cancer, a team at the University of Pittsburgh Medical Center set out to answer a deceptively simple question: do HER2-0, HER2-low, and HER2-positive tumors differ in when they metastasize, where they first spread, and how long patients survive after metastasis is diagnosed?

The stakes of that question are enormous because the HER2 axis was redrawn only recently. For decades, pathologists sorted breast tumors into a binary: those that amplified the human epidermal growth factor receptor 2 and those that did not. Then came the recognition of HER2-low disease, tumors that stain weakly positive for the protein on immunohistochemistry without gene amplification. The arrival of trastuzumab deruxtecan, an antibody-drug conjugate that showed striking activity in HER2-low advanced breast cancer, transformed this once-incidental staining pattern into a therapeutically meaningful category. Suddenly, the difference between an IHC score of 0 and 1+ could determine whether a patient received an entirely new class of drug.

In the study, the researchers classified patients as HER2-0, HER2-low, or HER2-positive and examined three outcomes: the metastasis-free interval, the first site of metastasis, and survival after metastatic diagnosis. The cohort was strikingly balanced at the low end of the HER2 spectrum. Some 647 patients, or 40.5 percent, had HER2-0 tumors, while 672, or 42 percent, had HER2-low tumors; the remaining 280 patients, 17.5 percent, had HER2-positive disease. Using chi-square tests, Welch one-way ANOVA, Kaplan-Meier estimation, and binary, ordinal logistic, and Cox regression models, the team compared outcomes across the three groups with and without adjustment for other clinical factors.

The first major finding concerned timing. HER2-positive tumors metastasized earliest, with a median metastasis-free interval of 2.7 years, compared with 3.3 years for HER2-low and 3.7 years for HER2-0 tumors, a difference that reached statistical significance at p = 0.002. When the researchers modeled the odds of late recurrence, defined as metastasis occurring five or more years after diagnosis, HER2-positive tumors carried markedly lower odds of late spread than HER2-0 tumors, with an odds ratio of 0.39 and a 95 percent confidence interval of 0.22 to 0.68. In other words, tumors that overexpress HER2 behave biologically like accelerants, seeding distant organs sooner after the original diagnosis.

By contrast, HER2-low tumors and HER2-0 tumors were statistically indistinguishable in metastatic timing. The median intervals of 3.3 and 3.7 years did not separate into distinct biologic rhythms once the data were examined carefully. This finding cuts against the hope, implicit in some earlier work, that low-level HER2 expression might mark a subtly different disease course in the interval between primary diagnosis and metastatic relapse. On the clock of metastasis, at least, HER2-low disease appears to run on the same schedule as HER2-0 disease.

The second question, where the cancer spreads first, produced a nuanced answer. In unadjusted analyses, the first metastatic site did differ across the HER2 groups, hinting that the biology of the three categories might shape organotropism, the tendency of cancer cells to colonize particular organs. But when the researchers adjusted for other clinical variables in binary logistic regression models, HER2 status was no longer independently associated with either bone-only or central nervous system-only presentations. The apparent differences in spread patterns, the analysis suggests, may reflect the company that HER2 status keeps, including hormone receptor status and other tumor characteristics, rather than a metastatic program driven by HER2 expression level itself.

Survival told a different and more hopeful story. In adjusted Cox regression models, both HER2-low and HER2-positive disease were associated with a lower hazard of death compared with HER2-0 disease. Patients with HER2-low tumors had a 15 percent reduction in the hazard of death, with a hazard ratio of 0.85 and a confidence interval of 0.74 to 0.97. Patients with HER2-positive tumors fared better still, with a 27 percent reduction in hazard, a hazard ratio of 0.73, and a confidence interval of 0.60 to 0.88. The paradox is notable: HER2-positive disease recurs earliest yet kills slowest after recurrence, a pattern the authors attribute in part to the extraordinary armamentarium of HER2-targeted therapies, from trastuzumab and pertuzumab to antibody-drug conjugates, that have reshaped the natural history of HER2-amplified metastatic disease.

The modest survival advantage of HER2-low disease over HER2-0 disease is harder to explain. The study was not designed to dissect mechanisms, but several candidates merit attention. Hormone receptor status, which strongly influences both prognosis and treatment options, may partly account for the difference, since HER2-low status is more common among hormone receptor-positive tumors. Differences in treatment exposure, including increasing use of antibody-drug conjugates in patients whose tumors express even low levels of HER2, may also contribute in more recent cohorts. Or the finding could reflect residual confounding that adjustment could not fully remove. The authors are appropriately measured: they conclude that HER2-low status is useful for outcome stratification but may not independently define a distinct metastatic phenotype.

The clinical implications ripple outward from that conclusion. The results reinforce the idea that HER2-low is best understood as a treatment-predictive biomarker rather than a wholly distinct biologic subtype. For patients whose tumors are HER2-low, the metastatic course, in timing and in pattern of spread, will look much like that of HER2-0 disease, and counseling and surveillance strategies need not differ on those grounds. Yet the observed survival difference suggests that HER2-low status still carries prognostic information, and the availability of trastuzumab deruxtecan means that accurate, guideline-concordant HER2 testing at both ends of the spectrum is more consequential than ever. The ASCO and College of American Pathologists guideline updates on HER2 testing have emphasized exactly this point: precision at the low end of the scale now changes therapy.

For researchers, the study opens as many questions as it closes. If HER2-low disease does not differ in metastatic timing or adjusted pattern of spread, what accounts for its post-metastatic survival edge, and is that edge shrinking or growing as antibody-drug conjugates enter earlier lines of therapy? Would prospective cohorts with central HER2 testing, genomic characterization of the kind performed in recent HER2-low versus HER2-0 genomic studies, and contemporary treatment data confirm these retrospective signals? The study was approved by the University of Pittsburgh Institutional Review Board and received no specific funding, and its authors, led by Ali Sanjari Moghaddam with corresponding author Margaret Q. Rosenzweig, note that patient-level data remain restricted but may be shared upon reasonable request. What the work delivers now is a clear-eyed baseline: in the metastatic setting, the HER2-low category earns its place in clinical decision-making not by redrawing the map of how breast cancer spreads, but by modestly rewriting its ending.

Subject of Research: Comparative metastatic behavior and post-metastatic survival across HER2-0, HER2-low, and HER2-positive metastatic breast cancer

Article Title: Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer

Article References: Sanjari Moghaddam, A., Deng, Z., Sereika, S. M., Habib, M., Homeniuk, A., Brufsky, A. M., & Rosenzweig, M. Q. (2026). Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer. Breast Cancer Research and Treatment, 219(3), Article 11. https://doi.org/10.1007/s10549-026-08067-4

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08067-4

Keywords: HER2-low breast cancer, HER2-0 breast cancer, HER2-positive breast cancer, metastatic breast cancer, metastasis-free interval, post-metastatic survival, first metastatic site, trastuzumab deruxtecan, biomarker stratification, hormone receptor status, breast cancer prognosis, oncology